Form 4: Director Timothy E. Davis Jr. Receives SI-BONE Equity Grant

SI-BONE, Inc. director Timothy E. Davis Jr. was granted 10,957 restricted stock units as part of his board compensation.

Summary

• Director Timothy E. Davis Jr. acquired 10,957 restricted stock units (RSUs) on June 4, 2026.
• Each RSU represents a contingent right to receive one share of SI-BONE common stock.
• The grant vests 100% on the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on continued board service.
• Following this transaction, the director's total beneficial ownership is 76,679 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The equity grant aligns the director's interests with those of shareholders through long-term stock ownership.

Negatives

• NA

Risks

• Vesting is subject to the director's continuous service on the Board of Directors.

Future Outlook

The RSU grant is subject to a one-year vesting schedule or the next annual general meeting, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the medical device industry to ensure alignment with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for mid-cap medical technology companies.
• The one-year cliff vesting period is standard for annual director equity awards.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation award.

Next Steps

• Vesting of the 10,957 RSUs upon the next annual general meeting or one year from the grant date.

Key Dates

Keywords

SI-BONE, SIBN, Form 4, Insider Trading, Equity Compensation, Director Compensation